# Elevian

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elevian

- Industry: Biotechnology
- Headquarters: US
- Website: www.elevian.com
- Total disclosed funding: $28M
- Latest round: Series A (Sep 16, 2021)
- Investors on record: 8

## About

Elevian, Inc. is a biotechnology company focused on developing innovative therapies for stroke recovery and age-related diseases, utilizing proprietary recombinant proteins to enhance recovery processes and improve patient outcomes.Founded in 2017 in the US, Elevian, Inc. specializes in biotherapeutics aimed at stroke recovery. The company has secured Series A funding, raising USD 22.72 mn in September 2021, led by Prime Movers Lab with participation from BOLD Capital Partners and Leslie Ventures. The firm has raised a total of USD 22.72 mn to date, and its current valuation stands at USD 89.25 mn. The CEO, Mark Allen, leads the company amidst its ongoing developments and strategic partnerships.Elevian's core product offering, rGDF11, is a recombinant protein designed to facilitate recovery from ischemic and hemorrhagic strokes. This therapy promotes neovascularization, stimulates neurogenesis, and reduces inflammation, targeting hospitals and rehabilitation centers across North America, Europe, and parts of Asia.Elevian's revenue model is driven by partnerships with healthcare institutions and potential pharmaceutical partners, primarily through licensing agreements and joint ventures. The company aims to establish B2B relationships with hospitals and direct partnerships with healthcare providers as it progresses rGDF11 through clinical trials toward market approval.Following its Series A funding of USD 22.72 mn in September 2021, Elevian, Inc. is focused on advancing treatments for stroke recovery and age-related diseases. The company is exploring new product developments and aims to expand its market presence in North America and Europe by 2023. The recent funding will support these initiatives as Elevian works towards clinical trials and eventual market entry.

## Funding rounds

- Series A, Sep 16, 2021, $23M — BOLD Capital Partners, Leslie Ventures, Prime Movers Lab
- Seed, Sep 6, 2018, $5.5M — Western Technology Investment, KIZOO Technology Ventures, The Longevity Fund, BOLD Capital Partners, Stanford-StartX Fund, Thynk Capital

## Investors

- Western Technology Investment (https://capitalatlas.ai/funds/western-technology-investment) — Seed
- KIZOO Technology Ventures (https://capitalatlas.ai/funds/kizoo-technology-ventures) — Seed
- The Longevity Fund (https://capitalatlas.ai/funds/the-longevity-fund) — Seed
- BOLD Capital Partners (https://capitalatlas.ai/funds/bold-capital-partners) — Seed, Series A
- Stanford-StartX Fund — Seed
- Thynk Capital (https://capitalatlas.ai/funds/thynk-capital) — Seed
- Leslie Ventures (https://capitalatlas.ai/funds/leslie-ventures) — Series A
- Prime Movers Lab (https://capitalatlas.ai/funds/prime-movers-lab) — Series A